Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02899299
Title Study of Nivolumab Combined With Ipilimumab Versus Pemetrexed and Cisplatin or Carboplatin as First Line Therapy in Unresectable Pleural Mesothelioma Patients (CheckMate743)
Recruitment Active, not recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors Bristol-Myers Squibb
Indications

malignant pleural mesothelioma

Therapies

Carboplatin + Cisplatin + Pemetrexed Disodium

Ipilimumab + Nivolumab

Age Groups: adult | senior
Covered Countries USA | ITA | FRA | DEU | BEL


No variant requirements are available.